NuVasive Earnings: Five Quarters of Double-Digit Revenue Growth

Although profit increased, NuVasive, Inc.’s (NASDAQ:NUVA) net income missed the mean analyst estimate. NuVasive, Inc. is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders.

Don’t Miss: Wall St. Cheat Sheet’s newest Feature Trades of the Month!

NuVasive Earnings Cheat Sheet for the First Quarter

Results: Net income for the medical instruments and supplies company rose to $2 million (6 cents/share) vs. $1.1 million (3 cents/share) in the same quarter a year earlier. A rise of 81.8% from the year earlier quarter.

Revenue: Rose 14.1% to $124.5 million YoY.

Actual vs. Wall St. Expectations: NUVA fell short of the mean analyst estimate of 19 cents/share. Estimates ranged from 16 cents per share to 26 cents per share.

Quoting Management: Alex Lukianov, Chairman and Chief Executive Officer, said, “Our financial performance in the first quarter of 2011 was excellent across all our key sectors. We generated revenue growth of over 14% and better than expected operating margin improvement in view of challenging spine market growth dynamics. Our performance internationally was a highlight, and is well on track to double this year to approximately 8% of revenue. We are pleased to be able to raise revenue guidance today in light of a marginally improved outlook for our U.S. lumbar business this year. As our focus shifts toward the achievement of our next milestone, the evolution of NuVasive into a $1 billion revenue company, we are laser focused on maintaining the startup mentality that is the very source of NuVasive’s success as a prolific new product innovator. With speed as our competitive edge, we expect to continue to sustain industry leading growth.”

Key Stats:

The company has enjoyed double-digit year-over-year revenue growth for the past five quarters. Over that span, the company has averaged growth of 26.6%, with the biggest boost coming in the first quarter of the last fiscal year when revenue rose 36.3% from the year earlier quarter.

Competitors to Watch: Alphatec Holdings, Inc. (NASDAQ:ATEC), Stryker Corporation (NYSE:SYK), Zimmer Holdings, Inc. (NYSE:ZMH), TranS1 Inc. (NASDAQ:TSON), Orthofix International NV (NASDAQ:OFIX), Medtronic, Inc. (NYSE:MDT), Exactech, Inc. (NASDAQ:EXAC), Wright Medical Group, Inc. (NASDAQ:WMGI), Orthovita, Inc. (NASDAQ:VITA), and RTI Biologics Inc. (NASDAQ:RTIX)

Stock Performance: Shares of NUVA are up 6.2% in after hours trading.

Don’t Miss Wall St. Cheat Sheet’s newest Feature Trades of the Month!